Picture of Eris Lifesciences logo

ERIS — Eris Lifesciences News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareBalancedMid CapFalling Star

Brief: Eris Lifesciences Sees Consol Revenue Growth Of 30% In FY23

Aug 5 (Reuters) - Eris Lifesciences Ltd  ERIS.NS :
    * SEES CONSOL REVENUE GROWTH OF 30% IN FY23
    * SEES CONSOL EBIDTA GROWTH OF 16-17% IN FY23

Source text for Eikon:  ID:nBSE4gV5V6 
Further company coverage:  ERIS.NS 

 ((Reutersbriefs@thomsonreuters.com;))

Recent news on Eris Lifesciences

See all news